 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > Biomarkers for Psychosis : |
|
visitant ::
identificació
|
|||||||||||||||
|
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > Biomarkers for Psychosis : |
(Instituto de Salud Carlos III (Barcelona)) (King's College London) (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) (Institut de Recerca Sant Pau) (Hospital Clínic i Provincial de Barcelona) (Instituto de Salud Carlos III (Barcelona)) (University of Oxford) (Hospital Clínic i Provincial de Barcelona) (King's College London) (King's College London)
| Data: | 2024 |
| Resum: | This umbrella review aims to comprehensively synthesize the evidence of association between peripheral, electrophysiological, neuroimaging, neuropathological, and other biomarkers and diagnosis of psychotic disorders. We selected systematic reviews and meta-analyses of observational studies on diagnostic biomarkers for psychotic disorders, published until February 1, 2018. Data extraction was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Evidence of association between biomarkers and psychotic disorders was classified as convincing, highly suggestive, suggestive, weak, or non-significant, using a standardized classification. Quality analyses used the Assessment of Multiple Systematic Reviews (AMSTAR) tool. The umbrella review included 110 meta-analyses or systematic reviews corresponding to 3892 individual studies, 1478 biomarkers, and 392 210 participants. No factor showed a convincing level of evidence. Highly suggestive evidence was observed for transglutaminase autoantibodies levels (odds ratio [OR] = 7. 32; 95% CI: 3. 36, 15. 94), mismatch negativity in auditory event-related potentials (standardized mean difference [SMD] = 0. 73; 95% CI: 0. 5, 0. 96), P300 component latency (SMD = -0. 6; 95% CI: -0. 83, -0. 38), ventricle-brain ratio (SMD = 0. 61; 95% CI: 0. 5, 0. 71), and minor physical anomalies (SMD = 0. 99; 95% CI: 0. 64, 1. 34). Suggestive evidence was observed for folate, malondialdehyde, brain-derived neurotrophic factor, homocysteine, P50 sensory gating (P50 S2/S1 ratio), frontal N -acetyl-aspartate, and high-frequency heart rate variability. Among the remaining biomarkers, weak evidence was found for 626 and a non-significant association for 833 factors. While several biomarkers present highly suggestive or suggestive evidence of association with psychotic disorders, methodological biases, and underpowered studies call for future higher-quality research. |
| Ajuts: | Agència de Gestió d'Ajuts Universitaris i de Recerca 2021/SGR-01475 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-01271 "la Caixa" Foundation 100010434 Instituto de Salud Carlos III PI19/00394 Instituto de Salud Carlos III PI22/00261 Agència de Gestió d'Ajuts Universitaris i de Recerca 2021/SGR-01128 |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Matèria: | Schizophrenia ; Psychotic disorders ; Peripheral biomarkers ; Electrophysiological biomarkers ; Neuroimaging biomarkers ; Neuropathological biomarkers |
| Publicat a: | Schizophrenia Bulletin Open, Vol. 5 (august 2024) , ISSN 2632-7899 |
